Matrix metalloproteinases: Regulation and dysregulation in the failing heart

Circulation Research

Volumn 90, Issue 5, 2002, Pages 520-530

  Spinale, Francis G ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Heart failure; Matrix metalloproteinase inhibitors; Matrix metalloproteinases; Myocardial remodeling

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; STROMELYSIN;

CONGESTIVE HEART FAILURE; DISEASE COURSE; ENZYME ACTIVITY; ENZYME REGULATION; GENE CONTROL; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; FEEDBACK, BIOCHEMICAL; HEART FAILURE, CONGESTIVE; HUMANS; MATRIX METALLOPROTEINASES; MYOCARDIUM; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR REMODELING;

EID: 0037155784     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000013290.12884.A3     Document Type: Review

References (88)

1. The myocardial matrix and the development and progression of ventricular remodeling
2. Connective tissue and the heart, functional significance and regulatory mechanisms
3. Inadequate collagen tethers in dilated cardiomyopathy
4. Role of extracellular matrix in dilated cardiomyopathy
5. Collagen remodeling after myocardial infarction in the rat heart
6. Remodeling and reparation of the cardiovascular system
7. Cardiac remodeling: Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling
8. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction
9. Integrins and the myocardium
10. Disruption of integrin function in the murine myocardium leads to perinatal lethality, fibrosis, and abnormal cardiac performance
11. 1 integrins are critical for fetal ventricular myocyte proliferation
12. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia
13. Inhibition of collagen cross-linking: Effects on fibrillar collagen and left ventricular diastolic function
14. Reduction in myocardial collagen cross-linking parallels left ventricular dilation in rat models of systolic chamber dysfunction
15. The matrix metalloproteinase family
16. Introduction to the matrix metalloproteinases (MMPs)
17. Matrix metalloproteinases: Effectors of development and normal physiology
18. Matrix metalloproteinases: Biologic activity and clinical implications
19. Matrix metalloproteinases: A review
20. Role of matrix metalloproteinases in normal and disease processes
21. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
22. Activation mechanisms of matrix metalloproteinases
23. Activation of the zymogen forms of MMPs
24. Relating matrix metalloproteinase structure to function: Why the "hemopexin" domain?
25. Membrane-type matrix metalloproteinases and cell surface-associated activation cascades for matrix metalloproteinases
26. Human membrane type-2 matrix metalloproteinase is defective in cell-associated activation of progelatinase A
27. Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase
28. Human membrane type-4 matrix metalloproteinase (MT4-MMP) is encoded by a novel major transcript: Isolation of complementary DNA clones for human and mouse mt4-mmp transcripts
29. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A overexpressed in brain tumors
30. Human MT6-matrix metalloproteinase: Identification, progelatinase A activation, and expression in brain tumors
31. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2
32. The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth
33. Functions of the TIMPs
34. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro: TIMP-3 promotes apoptosis
35. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
36. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells
37. Regulation of matrix metalloproteinase gene expression
38. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes
39. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease
40. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells
41. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA-3 and AP-1 binding sites
42. Transcriptional control of matrix metalloproteinase and the tissue inhibitors of matrix metalloproteinases
43. Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms
44. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1,-2, and -3 in rabbit aortic smooth muscle cells
45. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts: Synergistic effects of interleukin-1 and tumor necrosis factor-á on stromelysin expression
46. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-κB
47. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells
48. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily
49. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions
50. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: Relation to ventricular and myocyte function
51. Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function
52. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice
53. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type I (TIMP-1) on ventricular geometry and function in mice
54. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure
55. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control
56. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
57. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction
58. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure?
59. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure
60. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat
61. Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan
62. Congestive heart failure: Systolic and diastolic function
63. Relaxation and diastolic properties of the heart
64. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure
65. MMP/TIMP expression in spontaneously hypertensive heart failure rats: The effect of ACE- and MMP-inhibition
66. Extracellular matrix gene expression in the left ventricular tissue of spontaneously hypertensive rats
67. Contribution of ventricular remodeling to pathogenesis of heart failure in rats
68. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy
69. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure
70. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: Role of metalloproteinases and pyridinoline cross-links
71. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart
72. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices
73. Specialization at the Z line of cardiac myocytes
74. D) integrin and FAK are involved in cardiac myocyte hypertrophic response pathway
75. Decreased expression of tissue inhibitor of metalloproteinase I in stunned myocardium
76. Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro
77. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor
78. β-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction
79. Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation
80. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MM1270 (CGS27023A), in patients with advanced solid cancer
81. Synthetic inhibitors of matrix metalloproteinases
82. Clinical potential of matrix metalloprotease inhibitors in cancer therapy
83. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: Relation to myocardial fibrosis
84. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes
85. Time dependent alterations of serum matrix metalloproteinase-I and metalloproteinase-I tissue inhibitor after successful reperfusion of acute myocardial infarction
86. In vivo molecular target assessment of matrix metalloproteinase inhibition
87. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs
88. Three-dimensional organization of the connective tissue fibers of the human pancreas: A scanning electron microscopic study of NaOH treated-tissues